> Details

Johnson, Darryl; Carter, Melissa D.; Crow, Brian S.; Isenberg, Samantha L.; Graham, Leigh Ann; Erol, H. Akin; Watson, Caroline M.; Pantazides, Brooke G.; van der Schans, Marcel J.; Langenberg, Jan P.; Noort, Daan; Blake, Thomas A.; Thomas, Jerry D.; Johnson, Rudolph C.

Quantitation of ortho‐cresyl phosphate adducts to butyrylcholinesterase in human serum by immunomagnetic‐UHPLC‐MS/MS

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Quantitation of ortho‐cresyl phosphate adducts to butyrylcholinesterase in human serum by immunomagnetic‐UHPLC‐MS/MS
  • Contributor: Johnson, Darryl; Carter, Melissa D.; Crow, Brian S.; Isenberg, Samantha L.; Graham, Leigh Ann; Erol, H. Akin; Watson, Caroline M.; Pantazides, Brooke G.; van der Schans, Marcel J.; Langenberg, Jan P.; Noort, Daan; Blake, Thomas A.; Thomas, Jerry D.; Johnson, Rudolph C.
  • imprint: Wiley, 2015
  • Published in: Journal of Mass Spectrometry
  • Language: English
  • DOI: 10.1002/jms.3576
  • ISSN: 1076-5174; 1096-9888
  • Origination:
  • Footnote:
  • Description: <jats:p>Tri‐ortho‐cresyl phosphate (ToCP) is an anti‐wear, flame retardant additive used in industrial lubricants, hydraulic fluids and gasoline. The neurotoxic effects of ToCP arise from the liver‐activated metabolite 2‐(o‐cresyl)‐4H‐1,3,2‐benzodioxaphosphoran‐2‐one (cresyl saligenin phosphate or CBDP), which inhibits esterase enzymes including butyrylcholinesterase (BChE). Following BChE adduction, CBDP undergoes hydrolysis to form the aged adduct ortho‐cresyl phosphoserine (oCP‐BChE), thus providing a biomarker of CBDP exposure. Previous studies have identified ToCP in aircraft cabin and cockpit air, but assessing human exposure has been hampered by the lack of a laboratory assay to confirm exposure. This work presents the development of an immunomagnetic‐UHPLC‐MS/MS method for the quantitation of unadducted BChE and the long‐term CBDP biomarker, oCP‐BChE, in human serum. The method has a reportable range from 2.0 ng/ml to 150 ng/ml, which is consistent with the sensitivity of methods used to detect organophosphorus nerve agent protein adducts. The assay demonstrated high intraday and interday accuracy (≥85%) and precision (RSD ≤ 15%) across the calibration range. The method was developed for future analyses of potential human exposure to CBDP. Analysis of human serum inhibited <jats:italic>in vitro</jats:italic> with CBDP demonstrated that the oCP‐BChE adduct was stable for at least 72 h at 4, 22 and 37 °C. Compared to a previously reported assay, this method requires 75% less sample volume, reduces analysis time by a factor of 20 and demonstrates a threefold improvement in sensitivity. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.</jats:p>